Treatment Outcome of Vascular Depression
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00045773|
Recruitment Status : Completed
First Posted : September 11, 2002
Last Update Posted : October 31, 2017
|Condition or disease||Intervention/treatment|
|Depressive Disorder Depression||Drug: Sertraline|
Major late life depression (LLD) is an important health problem with a large and growing number of affected individuals. A significant subset of patients with LLD, particularly those with vascular depression, have abnormalities in certain parts of the brain that are evident on MRI scans and may be associated with poor acute and long-term response to antidepressant treatment. Studies have also indicated that LLD patients frequently have frontal lobe dysfunction. A longitudinal study with the antidepressant nortriptyline has demonstrated that frontal lobe dysfunction is associated with poor acute response and a greater risk for recurrence of LLD. However, it is not known if this finding applies to other antidepressants. This study will be the first clinical trial to simultaneously test the effects of specific brain and psychological factors on course of response, remission rate, and other measures of health outcomes in people with LLD.
Participants are treated with sertraline for 12 weeks. During this period, participants undergo cognitive testing, MRI, electrocardiogram (EKG), and laboratory tests. Study visits occur every 2 weeks.
|Study Type :||Observational|
|Actual Enrollment :||208 participants|
|Official Title:||Treatment Outcome of Vascular Depression|
|Study Start Date :||April 2001|
|Primary Completion Date :||April 2006|
|Study Completion Date :||April 2006|
50 - 200mg, once per day for 12 weeks.
Other Name: Zoloft
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00045773
|United States, Missouri|
|Washington University School of Medicine|
|Saint Louis, Missouri, United States, 63110|
|United States, North Carolina|
|Duke University Medical Center|
|Durham, North Carolina, United States, 27710|
|Principal Investigator:||Yvette I. Sheline, M.D.||Washington University Psychiatrist|
|Principal Investigator:||Murali Doraiswamy, M.D.||Duke University|